Guardant Health Raises FY24 Revenue Excluding Screening Outlook From $675M - $685M To $690M - $700M
Portfolio Pulse from Benzinga Newsdesk
Guardant Health has raised its FY24 revenue outlook excluding screening from $675M-$685M to $690M-$700M. The company expects non-GAAP gross margin excluding screening to be 61%-63% and total non-GAAP operating expenses to be $720-$730 million, representing a flat to 1% decrease compared to 2023. Free cash flow is expected to be $(275)-$(285) million, an improvement of $60M-$70M compared to 2023.
August 07, 2024 | 8:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guardant Health has raised its FY24 revenue outlook excluding screening to $690M-$700M. The company expects non-GAAP gross margin excluding screening to be 61%-63% and total non-GAAP operating expenses to be $720-$730 million, representing a flat to 1% decrease compared to 2023. Free cash flow is expected to improve by $60M-$70M compared to 2023.
The raised revenue outlook and improved free cash flow forecast are positive indicators for Guardant Health's financial health. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100